At the beginning of 2020, CONGEN was one of the first German companies to develop a molecular biological test for the detection of SARS-CoV-2. The continuously increasing demand for PCR tests is being met by CONGEN with great effort and engagement. The test is characterized by a high level of specificity and sensitivity, as independent studies show https://www.finddx.org/covid-19/sarscov2-eval-molecular/molecular-eval-results/. More than 10 million SARS-CoV-2 tests were produced for the national and international market in 2020. This could only be achieved with the cooperation of the entire team and the rapid expansion of production capacities and optimization of the kit formats offered. Flat hierarchies and a perfect coordination of the affected areas enabled us to be extremely flexible in our processes from development and production to the dispatch of the molecular biological tests to our distribution partner R-Biopharm AG in Darmstadt.
As a biocontent partner for several manufacturers of point-of-care solutions CONGEN supports fast and efficient testing directly on site. Point-of-care platforms are particularly suitable for use in mobile test stations as well as nursing and retirement homes. Fully automated and without large laboratory equipment, a test result is available within 30-45 minutes.
We would like to thank all partners for the excellent cooperation in this extraordinary time and we are confident that we will be able to master all new challenges together in 2021.